Financial Performance - The company's revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders increased by 7.63% to ¥28,792,801.97 from ¥26,751,469.21 year-on-year[5] - The basic earnings per share decreased by 18.64% to ¥0.48 from ¥0.59 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.7% compared to ¥170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached ¥28,678,469.89, an increase of 5.0% from ¥27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] - Basic and diluted earnings per share for the first quarter were CNY 0.48, down from CNY 0.59 in the previous year, indicating a decrease of about 18.6%[27] Cash Flow and Liquidity - The net cash flow from operating activities surged by 324.03% to ¥17,791,127.98, up from ¥4,195,764.85 in the previous year[14] - The company’s cash and cash equivalents decreased by 229.38% to -¥203,432,426.29, compared to -¥61,761,996.01 in the previous year, primarily due to increased cash outflows from investment activities[14] - The net increase in cash and cash equivalents for the quarter was -CNY 203,432,426.29, compared to -CNY 61,761,996.01 in the same period last year[30] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 year-over-year[30] - Cash outflow for investment activities was CNY 1,178,035,638.88, compared to CNY 201,445,738.79 in the previous year, resulting in a net cash flow from investment activities of -CNY 217,277,058.98[30] - The ending balance of cash and cash equivalents was CNY 1,317,740,627.75, down from CNY 299,533,862.88 at the end of the previous year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,922,065,259.29, reflecting a 2.19% increase from ¥1,880,941,437.34 at the end of the previous year[5] - Total liabilities increased to ¥299,243,667.60 in Q1 2023 from ¥286,982,213.23 in Q1 2022[23] - The company's total assets as of Q1 2023 amounted to ¥1,922,065,259.29, up from ¥1,880,941,437.34 in the previous year[23] - The total equity attributable to shareholders of the parent company was ¥1,616,942,691.17, compared to ¥1,587,985,580.78 in Q1 2022[23] Operational Metrics - Total operating costs for Q1 2023 were ¥135,498,900.38, slightly down from ¥136,102,405.20 in the previous year[24] - The total accounts receivable increased to ¥75,653,913.16 from ¥72,873,069.81, showing a growth of about 3.9%[21] - Inventory levels rose to ¥55,678,260.95 from ¥53,006,573.21, indicating an increase of approximately 5.0%[21] - The company reported cash received from sales of goods and services of CNY 153,077,038.71, an increase from CNY 136,263,341.28 in the prior year, reflecting a growth of approximately 12.3%[29] - Total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, indicating an increase of about 6.0%[30] Shareholder Relations and Governance - The number of shares held by the top ten unrestricted shareholders includes significant stakes from entities such as the Macau Monetary Authority and Kuwait Investment Authority, with holdings of ¥853,506.00 and ¥849,312.00 respectively[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] - The report indicates that there are no changes in restricted shares during the quarter[19] Strategic Focus and Future Outlook - The company is actively managing its financial assets, with a focus on optimizing liquidity and investment strategies[21] - The overall financial health of the company reflects a strategic approach to asset management and shareholder relations[21] - Future outlook includes potential market expansion and product development initiatives, although specific figures were not disclosed in the report[21] - Research and development expenses for Q1 2023 were ¥13,570,366.43, up from ¥12,565,071.46 in Q1 2022, indicating a focus on innovation[24] - The company did not report any new product launches or significant market expansion strategies during this quarter[31]

Financial Performance - The company's operating revenue for Q1 2023 was ¥160,932,583.88, a decrease of 5.47% compared to ¥170,242,153.31 in the same period last year[5] - Net profit attributable to shareholders increased by 7.63% to ¥28,792,801.97 from ¥26,751,469.21 year-on-year[5] - Basic earnings per share decreased by 18.64% to ¥0.48 from ¥0.59 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 160,932,583.88, a decrease of 5.7% compared to CNY 170,242,153.31 in Q1 2022[24] - Net profit for Q1 2023 reached CNY 28,678,469.89, an increase of 5.0% from CNY 27,307,384.49 in Q1 2022[26] - The total comprehensive income for the first quarter of 2023 was CNY 28,776,416.25, compared to CNY 27,327,655.65 in the same period last year, representing an increase of approximately 5.3%[27] Cash Flow and Investments - The net cash flow from operating activities surged by 324.03% to ¥17,791,127.98, compared to ¥4,195,764.85 in the previous year[14] - The company reported a cash inflow of CNY 153,077,038.71 from sales of goods and services, an increase from CNY 136,263,341.28 in the previous year, reflecting an increase of about 12.3%[29] - The total cash outflow from operating activities was CNY 141,395,795.77, compared to CNY 132,650,901.64 in the previous year, representing an increase of approximately 6.0%[30] - The net cash flow from investment activities was negative CNY 217,277,058.98, compared to negative CNY 17,572,346.41 in the same period last year, indicating a worsening of approximately 1,136.5%[30] - Cash inflow from investment activities totaled CNY 960,758,579.90, a substantial rise from CNY 183,873,392.38 in the previous year, reflecting an increase of about 421.5%[30] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,922,065,259.29, reflecting a significant increase of 187.20% from ¥669,236,394.13 at the end of the previous year[5] - Total liabilities increased to CNY 299,243,667.60 in Q1 2023, compared to CNY 286,982,213.23 in Q1 2022[23] - The company's total assets as of Q1 2023 amounted to CNY 1,922,065,259.29, up from CNY 1,880,941,437.34 in the previous year[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,657, with ACE UNION HOLDING holding 28.68% of the shares[15] - The first quarter report highlighted significant investments from major shareholders, including the Macau Monetary Authority and Kuwait Investment Authority, each holding approximately 1.42% of shares[18] - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest being the Macau Monetary Authority with 853,506 shares[18] - The company has established consistent action agreements among major shareholders to maintain alignment on significant corporate matters[18] Financial Management - The company reported a significant increase in financial income, with a rise of 593.41% in financial expenses due to increased exchange gains and interest income[12] - Other income increased by 470.83% to ¥3,874,649.00, primarily due to government subsidies related to revenue[12] - The company is actively managing its financial assets, with a focus on optimizing liquidity and investment strategies[21] Future Outlook - Future outlook includes potential market expansion and new product development, although specific figures were not disclosed in the report[20]

诺思格（北京）医药科技股份有限公司 2022 年第三季度报告 证券代码：301333 证券简称：诺思格 公告编号：2022-013 诺思格（北京）医药科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 3.第三季度报告是否经过审计 □是 否 1 诺思格（北京）医药科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 142,169,591.51 | -4.05% | 468,186,011.15 | 5.84% | | 归属于上市公司股东 | 22,536, ...

诺思格（北京）医药科技股份有限公司 2022 年半年度报告全文 诺思格（北京）医药科技股份有限公司 2022 年半年度报告 2022 年 8 月 1 诺思格（北京）医药科技股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人 WU JIE（武杰）、主管会计工作负责人赵倩及会计机构负责 人(会计主管人员)赵李林声明：保证本半年度报告中财务报告的真实、准确、 完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及未来的经营计划、业绩预测等方面的陈述，并不构成公司 对任何投资者及相关人士的实质性承诺，投资者及相关人士均应对此保持足 够的风险认识，并且应当理解计划、预测与承诺之间的差异。 公司在经营中可能面临的风险因素详见本报告"第三节管理层讨论与分 析"之"十、公司面临的风险和应对措施"相关内容，敬请广大投资者予以 关注，并注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 ...